Amiloride Is Effective in the Management of Abiraterone-Induced Mineralocorticoid Excess Syndrome without Interfering with Its Antineoplastic Activity.

Author: BedussiFrancesca, BerrutiAlfredo, Dalla VoltaAlberto, FerrariVittorio, FragniMartina, GalliDiego, LazzariBarbara, MemoMaurizio, RocaElisa, RossiniElisa, SigalaSandra, ValcamonicoFrancesca, VezzoliSara

Paper Details 
Original Abstract of the Article :
The administration of abiraterone acetate (abiraterone) leads to an adrenocorticotropic hormone (ACTH)-driven increase in mineralocorticoid hormones, requiring glucocorticoid supplementation that may stimulate the growth of prostate cancer (PCa). Amiloride is a drug that selectively reduces the aldo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1159/000477547

データ提供:米国国立医学図書館(NLM)

A New Twist on an Old Drug: Amiloride's Role in Managing Abiraterone-Induced Mineralocorticoid Excess Syndrome

Sometimes, the solution to a problem lies in an unexpected place. This research explores the use of amiloride, a drug traditionally used for heart conditions, in managing a side effect of abiraterone, a medication for prostate cancer.

A Side Effect With a Solution

Abiraterone can lead to an increase in mineralocorticoid hormones, which can cause fluid retention and high blood pressure. Amiloride, with its ability to block the effects of aldosterone, a key mineralocorticoid hormone, might be a valuable tool for managing this side effect. Imagine amiloride as a filter, preventing the excess mineralocorticoids from wreaking havoc on your body.

A Promising Approach

This research suggests that amiloride could potentially be a safe and effective treatment option for managing mineralocorticoid excess syndrome induced by abiraterone. This is an exciting development, as it might allow patients to continue receiving abiraterone treatment without experiencing the negative effects of mineralocorticoid excess.

Dr. Camel's Conclusion

Sometimes, the answer to a complex medical puzzle lies in revisiting old solutions and applying them in new ways. This research highlights the potential of amiloride, a drug that has been around for decades, in managing a side effect of a newer drug. It's a reminder that the world of medicine is constantly evolving, and old knowledge can often be repurposed to address new challenges.

Date :
  1. Date Completed 2018-07-13
  2. Date Revised 2018-07-13
Further Info :

Pubmed ID

28797006

DOI: Digital Object Identifier

10.1159/000477547

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.